Index

A
Abatacept, immunosuppression therapy, 270, 293
Activating transcription factor-4 (ATF4)
endoplasmic reticulum stress role, 52
unfolded protein response apoptotic switch, 61
Activating transcription factor-6 (ATF6)
endoplasmic reticulum stress sensing, 52, 57
unfolded protein response apoptotic switch, 61
Age of onset, T1D, 2
Altered peptide ligands (APLs), antigen-specific therapy, 251–252
Anakinra, anti-inflammatory therapy, 271–272, 291
Anti-inflammatory therapy
interleukin-1 antagonists
anakinra, 271–272
canakinumab, 272
islet engraftment promotion, 291
prospects, 277–278
tumor necrosis factor-α blockade, 271
Antigen-specific therapy
clinical trials, 245–246
dendritic cell engineering, 254–255
DNA vaccine
codelivery of antigen and immunomodulatory molecules, 253–254
glutamic acid decarboxylase, 253
heat shock protein-60, 253
insulin, 252–253
ethylene carbodiimide–fixed splenocyte, 255
major histocompatibility complex–based therapy
coated nanoparticles, 254
dimers, 254
mechanism of action, 247
preclinical studies, 243–244
prospects for study, 255–256
protein/peptide immunotherapy
altered peptide ligands, 251–252
dendritic cell–targeted peptide therapy, 251
glutamic acid decarboxylase, 242, 248, 277
heat shock protein-60, 250–262, 277
insulin, 248–250, 276–277
Antithymocyte globulin (ATG), tolerance induction, 29, 272–273
APLs. See Altered peptide ligands
Apoptosis
endoplasmic reticulum stress induction cell fate, 53
unfolded protein response components and therapeutic targeting, 59–63
inhibition for islet engraftment promotion, 291–292
APSI. See Autoimmune polyendocrine syndrome I
ATF4. See Activating transcription factor-4
ATF6. See Activating transcription factor-6
ATG. See Antithymocyte globulin
Autoantibodies
antigens. See Autoantigens
assay standardization and harmonization, 86, 88–89, 105
clinical relevance
autoimmune disease interrelationships, 96
children, 93–95
diagnostic and predictive value in T1D, 9–11
immunoglobulin G isotype, 97
Latent Autoimmune Diabetes of Adults, 96
specificity and T-cell response, 97
glutamic acid decarboxylase, 91
human leukocyte antigen allele correlations, 92–93
humoral autoimmunity in non-β-cell tissues, 98–99
IA-2, 91
immune therapy response, 105–106
insulin, 89–90
pathogenesis role in T1D, 97–98
prospects for study, 99
ZnT8, 91–92
Autoantigens. See also specific antigens
biomarker utilization, 162, 164
discovery based on autoantibody epitopes, 89
identification approaches, 155–156
immune therapy trial utilization, 162
polymorphisms, 161–162
posttranslational modification in production, 149–150
tolerance loss. See Tolerance
types, localization, and immune response, 87–88, 104–105, 163
Autoimmune polyendocrine syndrome I (APSI), gene mutations, 86
Autoimmunity. See also Tolerance
autoantigens. See Autoantibodies
human leukocyte antigen role. See Human leukocyte antigen
mechanisms in T1D, 8–9
T-cell autoreactivity. See T cell
Index

B
Bacterial infection, T1D risks, 183–184
B cell. See also Autoantibodies
  adaptive immunity in insulin resistance, 218
BCG, vaccination and atopy induction, 173
Bcl-2, unfolded protein response apoptotic switch, 62
Belatacept, immunosuppression therapy, 293
β cell
  embryonic stem cell differentiation
    culture protocols
      limitations, 42–43
      modifications, 43–44
    history of study, 40–41
    organogenesis in culture lessons from embryology, 41–42
    stem cell identification and isolation, 39–40
endoplasmic reticulum. See Endoplasmic reticulum stress
induced pluripotent stem cell differentiation, 44–45
insulin resistance and loss, 211–213
markers of destruction
  autoantibodies, 104–106
  autoreactive T cells, 106–108
  imaging, 110–112
  metabolic markers, 108–110
pancreas stem cells and fate plasticity, 45–46
proliferation studies in immunodeficient mice, 234
secretory granule autoantigen production, 128
Bioluminescence imaging, islet imaging, 112
Bone marrow transplantation, tolerance induction, 274–275
Breastfeeding, T1D studies, 13, 184–186
C-peptide, β-cell function assay, 109
CSA. See Cyclosporin A
CTLA-4. See Cytotoxic T lymphocyte associated-4
Cyclosporin A (CSA), immunosuppression therapy, 268–269
Cytotoxic T lymphocyte associated-4 (CTLA-4)
  abatacept for immunosuppression therapy, 270, 293
  pathogenic T-cell control, 22–23
  susceptibility gene in T1D, 8
  tolerance therapeutic targeting, 31

D
DC. See Dendritic cell
DEC-205, antigen-specific therapy, 251
Dendritic cell (DC)
  antigen presentation. See Human leukocyte antigen antigen-specific therapy, 251, 254–255
DNA vaccine. See Antigen-specific therapy

E
ECDI-SP. See Ethylene carbodiimide-fixed splenocyte
eIF2α, phosphorylation in endoplasmic reticulum stress, 55–56
ELISpot. See Enzyme-linked immunospot assay
Embryonic stem (ES) cell
  β-cell differentiation
    culture protocols
      limitations, 42–43
      modifications, 43–44
    history of study, 40–41
    organogenesis in culture lessons from embryology, 41–42
    stem cell identification and isolation, 39–40
Endoplasmic reticulum stress
  apoptosis induction
    cell fate, 53
    unfolded protein response components and therapeutic targeting, 59–63
  autoantigenicity contribution, 126–127
  diabetes role
    gestational diabetes, 59
    T1D, 57–58
    T2D, 57–59
  unfolded protein response mutations in rare diabetic syndromes, 54–57
  overview, 51–53
  secretory granule autoantigen production in β cells, 128

© 2012 by Cold Spring Harbor Laboratory Press
sensors, 52
Enterovirus (EV), infection and T1D risks, 181–183, 189, 196–197
Enzyme-linked immunospot assay (ELISPOT), autoreactive T-cell identification, 107
Eosinophil, interleukin-4 production in adipose tissue, 221
Epidemiology, T1D, 2–4
ES cell. See Embryonic stem cell
Etanercept, clinical trials, 271
Ethylene carbodiimide-fixed splenocyte (ECDI-SP), antigen-specific therapy, 255
EV. See Enterovirus
Exenatide, islet engraftment promotion, 292

F
Fertile field hypothesis, virus infection, 201
FoxP3, regulatory T-cell control, 24–25

G
GAD. See Glutamic acid decarboxylase
GCN2, endoplasmic reticulum stress function, 55–56
Genome-wide association study (GWAS), T1D susceptibility studies, 79–80
Geographic distribution
T1D, 3–4, 170, 172
tuberculosis, 170–171
GLP-1. See Glucagon-like peptide-1
Glucagon-like peptide-1 (GLP-1), islet engraftment promotion, 292
Glutamic acid decarboxylase (GAD) antigen-specific therapy
DNA vaccine, 253
peptide immunotherapy, 242, 248, 277
autoantibodies, 91
functional overview, 121
isoforms, 121–122
knockout mice, 122
synthesis and processing, 122
viral molecular mimicry, 199
Gluten, T1D studies, 186–187
Glycemic index, T1D risk studies, 188
Growth rate, T1D risk studies, 188
GWAS. See Genome-wide association study

H
Heat shock protein-60 (HSP60), antigen-specific therapy
DNA vaccine, 253
peptide immunotherapy, 250–252, 277
Helminthiasis, treatment and atopy induction, 173
Hemoglobin A1c, β-cell function, 110
HLA. See Human leukocyte antigen
HSP60. See Heat shock protein-60
Human leukocyte antigen (HLA) allele distribution, 72
antigen-specific therapy coated nanoparticles, 254
dimers, 254
autoreactive T-cell identification with tetramer staining
class I, 107–108
class II, 107
class I antigens, 72–73
class II antigens
antigen presentation to CD4+ T cells
conventional presentation, 139–142
unconventional peptide processing and presentation, 143–149
autoimmune disease association, 142–144
overview, 71–72
functional overview, 72–73
genotyping, 74–75
nomenclature, 73–74
structure, 70–71
susceptibility alleles in T1D autoantibody correlations, 92–93
class I antigens, 77–78
class II antigens DP, 77
DR-DQ, 76–77
non-HLA susceptibility loci in HLA region, 7–8, 78–79
overview, 7, 12, 69, 75–76, 180
prospects for study, 80–81
Hygiene hypothesis
animal model studies of autoimmune disease, 172–173
geographic distribution of diseases, 170–172
infection epidemiology and autoimmune disease control, 172
mechanisms of infection protection effects
immune response effects on lymphocytes, 175
infectious agents and protective constituents, 174
miscellaneous mechanisms, 176
Toll-like receptors, 175–176
overview in autoimmune disease, 11, 169–170
prospects for study, 176
therapeutic trial studies, 173
viral causation in confounding with T1D, 204

I
IA-2 (ICA512) antigen presentation, 125
autoantibodies, 91
knockout mice, 124
structure, 124
IBMR. See Instant blood-mediated inflammatory reaction
Unknown
Index

PD-1. See Programmed death-1
Peptidylarginine deimidase (PAD), autoantigen formation role, 149–150
PERK. See Protein kinase RNA-like endoplasmic reticulum kinase
Peroxisome proliferator activated receptor (PPAR), macrophage activation regulation, 219–220
PET. See Positron emission tomography
Positron emission tomography (PET), islet imaging, 111
PPAR. See Peroxisome proliferator activated receptor
Probiotics, atopy prevention, 173
Programmed death-1 (PD-1), pathogenic T-cell control, 22–23
Protein kinase RNA-like endoplasmic reticulum kinase (PERK)
eIF2α phosphorylation, 56
dendritic cell stress sensing, 52
knockout mouse, 54–56
unfolded protein response apoptotic switch, 61–63
PTPN22, susceptibility gene in T1D, 8, 79, 188–189

Q
Q-fever, vaccination and atopy induction, 173

R
Rituximab
autoantibody response, 105–106
immunosuppression therapy, 269–270
Rotavirus, infection and T1D risks, 183, 196
Rubella, infection and T1D risks, 196

S
SCID mouse. See Severe combined immunodeficiency mouse
Seasonality, T1D onset, 3
Severe combined immunodeficiency (SCID) mouse
β-cell proliferation studies, 234
Hu-PBL-SCID model, 234
Hu-SRC-SCID model, 234–235
human comparison
immune system, 228–229
islets, 228
human immune system engraftment, 229–230
interleukin-2 receptor common γ-chain knockout, 229–230
NOD-Scid Il-2rnull Tg(Ins-rtTA) Tg(TET-DTA) strain, 233

O
Obesity. See Macrophage
OKT3, islet engraftment promotion, 292
Old friends hypothesis, overview, 11–12

P
PAD. See Peptidylarginine deimidase
Pathogenesis, T1D models, 4–6
Index

Severe combined immunodeficiency (SCID) mouse
(Continued)
NOD-Scid Il-2rγnull Tg(RIP-HuDTR) strain, 233–234
NSG mouse
monogenetic models of T1D, 232
normoglycemic mouse, 231
overview, 230–231
streptozotocin-induced diabetes studies, 231
Single-photon emission computed tomography (SPECT), islet imaging, 111
SPECR. See Single-photon emission computed tomography
Splenocyte. See Ethylene carbodiimide-fixed splenocyte
Stem cell therapy
β differentiation. See β cell concerns, 46–47
pancreas stem cells and fate plasticity, 45–46
prospects, 47
T1D as good model, 40
Streptococcus pneumoniae, vaccination and atopy induction, 173

T
T cell
adaptive immunity in insulin resistance, 218
autoantibody specificity and T-cell response, 97
autoreactive T-cell identification
enzyme-linked immunospot assay, 107
immunoblot, 106
major histocompatibility complex tetramer staining
class I, 107–108
class II, 107
proliferation assay, 106–107
bystander activation in virus infection, 200–201
class II antigen presentation to CD4+ T cells
conventional presentation, 139–142
unconventional peptide processing and presentation, 143–149
immune response regulation in hygiene hypothesis, 175
pathogenic T cells in tolerance dysfunction
activation and function, 20–22
extrinsic control, 23–26
intrinsic control, 22–23
tolerance loss mechanisms with T1D autoantigens
CD4 T cell targets, 158–159
CD8 T cell targets, 159–160
prospects for study, 164–165
Tacrolimus, islet engraftment promotion, 292
TG-2. See Tissue transglutaminase-2
Threshold hypothesis, overview, 12
Tim-3, pathogenic T-cell control, 23
Tissue transglutaminase-2 (TG-2), autoantigen formation role, 149
TLRs. See Toll-like receptors
TNF-α. See Tumor necrosis factor-α
Tolerance
induction therapy
antigen-specific therapy. See antigen-specific therapy
antilymphocyte globulin, 272–273
bone marrow transplantation, 274–275
CD3 antibodies, 273–274
overview, 266, 268, 272
loss mechanisms with T1D autoantigens
autoantigen polymorphisms, 161–162
CD4 T-cell targets, 158–159
CD8 T-cell targets, 159–160
islet epitopes and thymic selection, 160–161
overview, 156–158
prospects for study, 164–165
protein modifications, 161
microRNA regulation, 27–29
pathogen exposure and gut microflora, 26–27
pathogenic T cells
activation and function, 20–22
extrinsic control, 23–26
intrinsic control, 22–23
therapeutic targeting, 29–31
Toll-like receptors (TLRs), hygiene hypothesis studies, 175–176
Tumor necrosis factor-α (TNF-α) blockade, 271, 291
susceptibility gene studies, 78
Twin studies, T1D, 5

U
Unfolded protein response. See Endoplasmic reticulum stress

V
Virus infection, T1D risks
animal models
bystander activation, 200–201
fertile field hypothesis, 201
islet-specific infection, 199–200
molecular mimicry, 199–200
mouse, 197–199
rat, 198–199
Coxsackie virus, 182–183, 202, 204
direct evidence, 202–203
enterovirus, 181–183, 189, 196–197
hygiene hypothesis confounding, 204
immunization strategies, 204
mumps, 196
pancreas infection evidence in humans prospects for study, 204
rotavirus, 183, 196
rubella, 196
temporal divergence of viral insult and clinical onset, 203
viral signature, 201–202
virus-specific responses, 203–204
Vitamin D
deficiency and T1D risks, 13–14, 187–188
immunosuppression therapy, 270–271

W
WFS1, knockout mouse, 56
Wolfram syndrome, diabetes, 56

Z
ZnT8
autoantibodies, 91–92
functional overview, 122–123
knockout mice, 124
polymorphisms, 161–162